Literature DB >> 24888694

National and international guidelines for rectal cancer.

L B J Nielsen1, P Wille-Jørgensen.   

Abstract

AIM: Rectal cancer is a common malignancy. Differences in daily practice may influence the morbidity and mortality, and many national and international organizations have created guidelines for staging and treatment of rectal cancer. Even though consensus is reached within individual guidelines, this might not be the case between guidelines. No formal evaluation of the contrasting guidance has been reported.
METHOD: A systematic search for national and international guidelines on rectal cancer was performed. Eleven guidelines were identified for further analysis.
RESULTS: There was no consensus concerning the definition of rectal cancer. Ten of the 11 guidelines use the TNM staging system and there was general agreement regarding the recommendation of MRI and CT in rectal cancer. There was consensus concerning a multidisciplinary approach, preoperative chemoradiotherapy (CRT) and total mesorectal excision (TME). There was no consensus concerning local treatment of T1 tumours and adjuvant therapy, and not all guidelines included metastatic disease and recurrence. There was no consensus on the protocol for follow up. The guidelines had different approaches to evidence. All referred to evidence but not all considered the level of evidence.
CONCLUSION: The intention of the study was to provide an overview of international guidelines for rectal cancer based on the underlying evidence, but despite hard evidence it was very difficult to reach general conclusions. Despite much knowledge, there is no international consensus on guidelines for the staging and treatment of rectal cancer. Colorectal Disease
© 2014 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Rectal cancer; guidelines; recommendations

Mesh:

Year:  2014        PMID: 24888694     DOI: 10.1111/codi.12678

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  13 in total

1.  [Tumor regression after neoadjuvant short-term irradiation for rectal cancer].

Authors:  P Mroczkowski; C J Bruns
Journal:  Chirurg       Date:  2015-09       Impact factor: 0.955

Review 2.  How Should Imaging Direct/Orient Management of Rectal Cancer?

Authors:  Jemma Bhoday; Svetlana Balyasnikova; Anita Wale; Gina Brown
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

Review 3.  Evolution of Surgical Treatment for Rectal Cancer: a Review.

Authors:  Sanjeev Dayal; Nick Battersby; Tom Cecil
Journal:  J Gastrointest Surg       Date:  2017-04-25       Impact factor: 3.452

4.  The Log Odds of Positive Lymph Nodes Stratifies and Predicts Survival of High-Risk Individuals Among Stage III Rectal Cancer Patients.

Authors:  Christina W Lee; Katheryn H Wilkinson; Adam C Sheka; Glen E Leverson; Gregory D Kennedy
Journal:  Oncologist       Date:  2016-03-14

5.  Prognostic significance of neutrophil-to-lymphocyte ratio in rectal cancer: a meta-analysis.

Authors:  Yi-Wei Dong; Yan-Qiang Shi; Li-Wen He; Pei-Zhu Su
Journal:  Onco Targets Ther       Date:  2016-05-25       Impact factor: 4.147

6.  Feasibility and response of helical tomotherapy in patients with metastatic colorectal cancer.

Authors:  Sun Hyun Bae; Seong Kwon Moon; Yong Ho Kim; Kwang Hwan Cho; Eung Jin Shin; Moon Sung Lee; Chang Beom Ryu; Bong Min Ko; Jina Yun
Journal:  Radiat Oncol J       Date:  2015-12-30

7.  Trends with neoadjuvant radiotherapy and clinical staging for those with rectal malignancies.

Authors:  Sanjay S Reddy; Beth Handorf; Jeffrey M Farma; Elin R Sigurdson
Journal:  World J Gastrointest Surg       Date:  2017-04-27

8.  Intravoxel Incoherent Motion Diffusion-Weighted Imaging of Primary Rectal Carcinoma: Correlation with Histopathology.

Authors:  Baolan Lu; Xinyue Yang; Xiaojuan Xiao; Yan Chen; Xu Yan; Shenping Yu
Journal:  Med Sci Monit       Date:  2018-04-21

9.  Surgical Quality in Rectal Cancer Management: What Can Be Achieved by a Voluntary Observational Study?

Authors:  Łukasz Dziki; Ronny Otto; Hans Lippert; Paweł Mroczkowski; Olof Jannasch
Journal:  Gastroenterol Res Pract       Date:  2018-05-08       Impact factor: 2.260

10.  A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.

Authors:  Nick J Battersby; Mit Dattani; Sheela Rao; David Cunningham; Diana Tait; Richard Adams; Brendan J Moran; Shelize Khakoo; Paris Tekkis; Shahnawaz Rasheed; Alex Mirnezami; Philip Quirke; Nicholas P West; Iris Nagtegaal; Irene Chong; Anguraj Sadanandam; Nicola Valeri; Karen Thomas; Michelle Frost; Gina Brown
Journal:  Trials       Date:  2017-08-29       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.